Asset
MATRIX-M1 ADJUVANT
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04533399 | phase2 | completed | 2020-08-17 | 2021-12-07 | Novavax | A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults |
| NCT04583995 | phase3 | completed | 2020-09-28 | 2022-03-29 | Novavax | A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom |
| NCT04611802 | phase3 | completed | 2020-12-27 | 2023-04-10 | Novavax | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 |
| NCT03026348 | phase2 | completed | 2017-01-01 | 2017-04-01 | Novavax | Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults |
| NCT05468736 | phase2_3 | completed | 2022-07-22 | 2024-01-16 | Novavax | Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years |
FDA applications (0)
This company has no applications containing this asset.